NCT02354703View on ClinicalTrials.gov

Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

293

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Alcohol Use Disorder
Interventions
DRUG

Ondansetron

Ondansetron (0.33 mg) bid+ BBCET counseling

DRUG

Placebo

Placebo + BBCET counseling

Trial Locations (3)

19103

University of Pennsylvania Treatment Research Center, Philadelphia

19104

Philadelphia VAMC, Philadelphia

21228

MPRC, Baltimore

All Listed Sponsors
collaborator

University of Pennsylvania

OTHER

lead

University of Maryland, Baltimore

OTHER

NCT02354703 - Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder | Biotech Hunter | Biotech Hunter